



# Drug Coverage Decision for BC PharmaCare

## About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

## Details of Drug Reviewed

<b>Drug</b>	<b>deucravacitinib</b>
Brand name	Sotyktu™
Dosage form(s)	6 mg tablet
Manufacturer	Bristol-Myers Squibb
<b>Submission type</b>	<b>New Submission</b>
Indication reviewed	The treatment of adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy
Canada's Drug Agency (CDA-AMC) recommendation Clinical Reimbursement Review (CRR)	CDA-AMC recommended: <b>Do Not Reimburse</b> .  Visit the CRR website for more <a href="#">details</a> .
Drug Benefit Council (DBC)	Deucravacitinib was reviewed internally and was not reviewed by the DBC because it received a "do not reimburse" recommendation from the CDA-AMC.
<b>Drug Coverage Decision</b>	<b>Non-benefit</b>
Date	July 25, 2024
Reason(s)	Drug coverage decision is consistent with the Canadian Drug Expert Committee (CDEC) recommendation that deucravacitinib not be reimbursed. <ul style="list-style-type: none"> <li>The evidence from 2 clinical trials was insufficient to determine that deucravacitinib offered treatment benefits over currently available advanced treatments in Canada for the treatment of moderate to severe PsO in adults.</li> </ul>

- No evidence was found that directly compared deucravacitinib to newer biologic treatments, and the indirect evidence suggested that deucravacitinib was less effective at improving skin plaques than several biologics that are available and reimbursed in Canada.
- CDEC concluded that there was insufficient evidence to demonstrate that deucravacitinib meets the needs that are not already addressed by other available treatments for the treatment of moderate to severe PsO in adults.
- The pan-Canadian Pharmaceutical Alliance (pCPA) was not involved in negotiations with the manufacturer for this product for majority of the participating jurisdictions including BC because of the CDEC recommendation not to reimburse.

### The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug and Health Technology Agency \(CADTH\)](#)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.